Turnkey Platform Dalriada offers a TURN-KEY model that aligns R&D with business goals and IP, making it attractive to early-stage biotech startups and mid-size pharma seeking rapid project progression and integrated value building. Their in-house MedChem, Biology and ADME capabilities, plus iCLASS live-cell chemoproteomics, enable fast end-to-end discovery and faster progression.

Strategic Collaborations Recent partnerships with SpiroChem AG and Toposbio demonstrate a collaboration-centric model to access protein mass spectrometry and chemoproteomics for challenging targets, offering potential customers a way to accelerate discovery and share risk. BD approach: target CROs and biotech companies working on dynamic targets, provide joint development and access to in-house platform.

North American Advantage All R&D operations are located in Mississauga, providing a local nearshore capability for North American clients, favorable IP protection and time-zone alignment, and easier regulatory engagement. Position to attract Canadian and US biotechs needing integrated discovery without offshoring.

Platform Expansion The public launch of iCLASS signals an expanding platform for live-cell chemoproteomics in early-stage discovery, offering customers enhanced target engagement data and faster progression to lead candidates. This can be cross-sold with MedChem, Biology and ADME services to broaden engagement.

Leadership Credibility A leadership team with pharma collaborations and senior industry hires strengthens credibility for enterprise partnerships and sponsored research. This can help open doors with portfolio teams and joint venture opportunities for expanding the discovery platform.